Objective: Adipose tissue is closely associated with angiogenesis, but the mechanisms are not fully understood. Some of the adipocyte-derived cytokines are hypothesized to play an important role in angiogenesis. We evaluated tube formation of human umbilical vascular endothelial cells (HUVECs) cultured in type I collagen gel when overlaid with the supernatant of 3T3-L1 cell culture, and expression of tube-forming factor(s) in 3T3-L1 cells with or without pioglitazone. We also studied plasma growth factor levels in patients with type 2 diabetes mellitus treated with pioglitazone. Results and methods: The supernatant of 3T3-L1 cells increased tube formation of HUVECs by 9.03-fold of control. Reverse transcription-polymerase chain reaction showed that hepatocyte growth factor (HGF) and vascular endothelial growth factor (VEGF) mRNA were expressed in 3T3-L1 cells. Western blot analysis also demonstrated HGF and VEGF protein expression. When 3T3-L1 cells were treated with 100 nM small interfering RNAs (siRNAs) for HGF, the HGF mRNA and protein were suppressed. The VEGF mRNA and protein in the cells were also suppressed by siRNA for VEGF. The supernatant of 3T3-L1 cells treated with HGF siRNA suppressed tube formation of HUVECs by 61% compared with the supernatant of cells treated with control siRNA. Addition of VEGF siRNA resulted in no significant changes. The supernatant conditioned with pioglitazone further promoted the tube formation. Pioglitazone enhanced HGF mRNA expression in 3T3-L1 cells. After 12 weeks of pioglitazone treatment, the changes of plasma HGF levels in patients treated with pioglitazone were significantly higher than those in control. Conclusion: These results suggest that HGF secreted from 3T3-L1 cells may be the major factor regulating the tube formation, and agents that enhance the differentiation of adipocytes may promote tube formation of HUVECs mediated by HGF secreted by adipocytes.
Introduction
Angiogenesis is the formation of new blood vessels by capillary sprouting from pre-existing vessels. Angiogenesis is a complex phenomenon, which includes proteolytic degradation of matrix, migration, proliferation and tube formation by vascular endothelial cells. 1 Especially, tube formation is recognized as a specific phenomenon for vascular endothelial cells, and it is possible to study the tube formation using vascular endothelial cells cultured in type 1 collagen gel. Adipose tissue is closely associated with angiogenesis. Hausmann et al. 2 have reported differentiation of capillaries concurrent with adipogenesis in perivascular preadipocytes.
Excessive growth of adipose tissue may require the formation of new capillaries for proper functioning. 3 However, the mechanisms by which adipose tissue induces angiogenesis are not fully understood. Adipose tissue is now recognized as an endocrine organ that secretes many cytokines and growth factors. 4, 5 For example, several reports have demonstrated that adipocytes secrete tumor necrosis factor alpha, 6 resistin, 7 plasminogen activator inhibitor-1 (PAI-1), 8 leptin 9 and angiotensinogen. 10, 11 Vascular endothelial growth factor (VEGF) is an angiogenetic growth factor, which is secreted by rat adipose tissue ex vivo. 12 Vascular endothelial growth factor is considered to be the most potent and specific of the growth factors that regulate angiogenesis. Hepatocyte growth factor (HGF) is another endothelial growth factor with potent angiogenetic and mitogenic effects. 13, 14 Recently, HGF as well as VEGF are being used in 'therapeutic angiogenesis'. 15, 16 Serum HGF levels are elevated not only in patients with hepatic desease. 17 Rehman et al. 18 reported that levels of circulating HGF correlated with body mass index (BMI), and that HGF mRNA expression as measured by reverse transcription-polymerase chain reaction (RT-PCR) was increased in cultured adipocytes. However, the role of those cytokines secreted by adipocytes in tube formation of cultured vascular endothelial cells is not fully understood. Some of the adipocyte-derived growth factors are hypothesized to promote tube formation of vascular endothelial cells. Therefore, we studied whether the factors secreted by 3T3-L1 cells induce tube formation of human umbilical venous endothelial cells (HUVECs) cultured in type 1 collagen gel. Next, we attempted to identify the tubeforming factor secreted by adipocytes by conducting RNA interference assays using small interfering RNAs (siRNAs) 19 targeting VEGF and HGF. Furthermore, we hypothesized that the increased presence of secretory adipose tissue would result in systemic elevations of VEGF and HGF. We also studied the plasma VEGF and HGF levels in patients with type 2 diabetes mellitus treated with pioglitazone, which was used to enhance differentiation of adipocytes.
Materials and methods
Human umbilical venous endothelial cell culture Human umbilical venous endothelial cells were supplied by Cambrex Bio Science (Walkersville, Inc, Maryland, USA). The cells in endothelial cell basal medium (EBM; Cambrex, Co., East Rutherford) supplemented with 2.0% fetal calf serum (FCS) were seeded at a density of 2.0 Â 10 4 cells in a 12-well plate. The medium was replaced once after 48 h. All experiments were performed on quiescent cells from the first passage.
In vitro tube formation assay Eight volumes of type 1 collagen solution (Vitrogen 100; Collagen Corp., Santa Clara, CA, USA), 1 volume of 0.1 N NaOH and 1 volume of 10 Â Dulbecco's modified Eagle's minimal essential medium (DMEM) were mixed on ice. A volume of 0.75 ml of the collagen mixture was dispensed into a well of a 12-well plate and allowed to gel at 371C. 1 Â 10 5 HUVECs in DMEM supplemented with 10% FCS were plated onto the collagen gel and cultured for 24 h at 371C under 5% CO 2 . Then, the medium was aspirated, and the cells were overlaid with 0.5 ml of the collagen mixture. After setting, 1.0 ml of DMEM containing the test factor was added. After 24 h incubation, the formation of capillary-like structure by HUVECs was observed.
Quantitative analysis of network structures
Phase-contrast photomicrographs ( Â 100 magnification) were recorded on a digital camera. The total length of the network structures was measured using the Scion Image software (Scion, Co., Washington, DC, USA). In all, 10 random fields were measured and the total length per field was calculated and expressed as a ratio to the control. In the control well, 1.0 ml of DMEM supplemented with 10% FCS was overlaid on the HUVEC culture in type 1 collagen mixture.
3T3-L1 cell culture
Mouse 3T3-L1 cells in DMEM supplemented with 10% FCS were cultured at 371C under 5% CO 2 . The cells (2.5 Â 10 4 per well) were dispensed in a 12-well plate and incubated for 48 h. Then, the cells were incubated in the above-mentioned medium supplemented with dexamethasone (0.25 mM), 3-isobutyl-1-methyxanthine (0.5 mM) and insulin (10 mg/ml) for another 2 days. After incubation, the medium was replaced with DMEM containing 10% FCS with or without pioglitazone (endowed by Takeda Pharmaceutical Co., Ltd, Osaka) dissolved in dimethyl sulphoxide at a final concentration of 10 mM and incubated for 72 h. Pioglitazone was used to enhance differentiation of the 3T3-L1 cells. Then, the medium was replaced with DMEM supplemented with 10% FCS. After 24 h incubation, 1.0 ml of the supernatant was overlaid on type 1 collagen mixture containing HUVECs.
RNA interference of 3T3-L1 cells
To identify the angiogenetic factor secreted from 3T3-L1 cells, we performed RNA interference assays on 3T3-L1 cells using siRNAs (Ambion, Inc., Austin, TX, USA). Murine HGF siRNAs targeting the sense sequence 5 0 -GGU GGA GAA GAG AGC Utt-3 0 and the antisense sequence 5 0 -AGC UCU CUU CUU CUC CAC Ctg-3 0 were selected. Murine VEGF siRNAs targeting the sense sequence 5 0 -GGA GAG CAG AAG UCC CAU Gtt-3 0 and the antisense sequence 5 0 -CAU GGG ACU UCU GCU CUC Ctt-3 0 were also selected. Silencert (Ambion, Inc.) siRNA was used as the negative control. Mouse 3T3-L1 cells were cultured in DMEM with 10% FCS for 48 h, then the cells were incubated in the above-mentioned medium with dexamethasone, 3-isobutyl-1-methyxanthine and insulin for another 2 days. The siPORTt amine (Ambion, Inc.) was diluted in serum-free minimum essential medium and kept at room temperature for 30 min. Then, 5 or 10 ml of 20 mM siRNA (final concentration 50 or 100 nM for murine HGF or VEGF (Ambion, Inc.) was added to the diluted siPORTt amine transfection agent and left at room temperature for 15 min. After adjustment the volume of normal DMEM in each well containing cells to 400 and 100 ml of the transfection agent/siRNA mixture was added and incubated at 371C for 24 h. Then, 2 ml of fresh medium was added to each well and the cells were incubated for 24 h. After incubation, the supernatant and cells were used for studies. 0 ; First-strand cDNA was synthesized from 1 mg of total RNA. Total RNA was mixed with 0.25 U of reverse transcriptase, 1 mM of deoxynucleoside triphosphate mixture, 2.5 mM of first-strand cDNA primer (random 9 mers; Takara, Ohtsu, Japan), 0.25 U of RNase inhibitor and 6 ml of MgCl 2 reaction buffer in a final volume of 10 ml and incubated at 301C for 10 min, followed by 30 min at 421C, 5 min at 991C and 5 min at 51C. The PCR mixture contained 0.4 mM of each primer, 0.25 ml of Takara Ex Taq HSt as DNA polymerase and 5.0 mM of MgCl 2 reaction buffer in a final volume of 40 ml for synthesizing the secondstrand cDNA. Amplification was performed for 30 cycles under the following conditions: denaturation at 951C for 5 min for the first cycle and 30 s for subsequent cycles, annealing at 551C for 30 s and extension at 721C for 90 s. The PCR products were separated by electrophoresis on a 3.0% agarose gel, and then visualized by staining with 1 mg/ml ethidium bromide. The quantities of reaction products were determined using digital scanning and Scion Image software.
Western blot analysis of hepatocyte growth factor or vascular endothelial growth factor protein in 3T3-L1 cells Hepatocyte growth factor and/or VEGF protein expression in 3T3-L1 cells was detected by Western blot analysis. Cells were suspended in a lysis buffer containing 10 mM Tris-HCl (pH 7.5), 150 mM NaCl, 0.5% Triton X-100, 0.5 mM phenylmethylsulfonyl fluoride and 1 mM ethylenediamine tetraacetate (EDTA) for 4 h at 41C. After centrifugation at 12 000 g, the protein concentration in the supernatant was measured using the Bio-Rad protein assay. Samples were diluted 1:1 with electrophoresis sample buffer containing 100 mM Tris (pH 6.8), 10% sodium dodecyl sulfate (SDS), 10% glycerol, 0.1% bromophenol blue and 5% b-mercaptoethanol. They were boiled for 5 min and electrophoresed on 10% SDSpolyacrylamide gel. The proteins were transferred onto Hybond-ECL nitrocellulose membrane (Amersham, Piscataway, NJ, USA). After blotting, the membrane was washed with Tris buffer saline (TBS; 100 mM Tris, pH 7.5, 0.9% NaCl) and blocked with 5% bovine serum albumin in TBS, followed by a brief wash in TBS containing 0.1% Tween-20 (TTBS) and incubation with antiserum against murine HGF (Santa Cruz Biotechnology, Inc., CA, USA) and murine VEGF (TECNE corporation, Minneapolis, MN, USA) at a dilution of 1:500 for 2 h at room temperature. After washing with TTBS, the blot was incubated with peroxidase-labeled affinity-purified antibody to chicken immunoglobulin-G (H þ L) (KPL, UK) at a dilution of 1:1500 for 1 h at room temperature, washed with TTBS and incubated with 1:3000 diluted biotinylated HP streptavidin complex for 1 h at a room temperature. The antigen-antibody complex was visualized by photo detection. The reaction products were quantified using digital scanning and Scion Image software.
Subjects
The randomized, open study was performed at the Center of Diabetes, Endocrinology and Metabolism, Sakura Hospital, School of Medicine, Toho University. A total of 50 Japanese subjects (29 males and 21 females) with type 2 diabetes mellitus, who had not been treated with pioglitazone, were eligible for enrollment. Patients with cancer, myocardial infarction, cerebral infarction and arteriosclerosis obliterans were excluded from this study. Before administration of pioglitazone, 34 patients had been treated with sulfonylureas and 16 had been treated with diet alone. The same dose of sulfonylureas had been continued during pioglitazone administration. The patients were randomly divided into two groups. One group was administered pioglitazone 30 mg/day (pioglitazone group, n ¼ 25) and the other group was not administered (control group, n ¼ 25) for 12 weeks. Clinical characteristics of this study subject are shown in Table 1 . Dietary counseling was undertaken by a dietary assistant and patients were asked to avoid any changes in diet or lifestyle for the duration of the study. The study was approved by the institutional review board and all patients provided written informed consent before participation in the study.
Measurement of plasma hepatocyte growth factor and vascular endothelial growth factor Blood samples were withdrawn in the morning after 12 h of fasting. The samples were collected in tubes containing di-sodium EDTA, centrifuged at 3000 g for 10 min at 41C and frozen at À801C. Plasma HGF levels were determined by using enzyme-linked immunosorbent assay (ELISA) kits (HGF Otsuka ELISA kit, Otsuka, Tokyo) and plasma VEGF levels were determined by using ELISA kits (human VEGF Quantikine, R&D Systems, Minneapolis, MN, USA).
Statistical analysis
Stat View-J 5.0 software was used for all statistical analysis. Paired t-test was carried out to determine if the differences between groups were statistically significant. Po0.05 was considered to be significant. Hepatocyte growth factor and/or vascular growth factor mRNA expression in 3T3-L1 cells conditioned with pioglitazone Figure 1 shows that the supernatant of differentiated 3T3-L1 cells conditioned with pioglitazone further promoted the HGF secreted by adipocytes promote angiogenesis A Saiki et al HGF secreted by adipocytes promote angiogenesis A Saiki et al HGF secreted by adipocytes promote angiogenesis A Saiki et al tube formation compared with the supernatant of the cells conditioned without pioglitazone. To clarify the tubeforming factor(s) in 3T3-L1 cells enhanced by addition of pioglitazone, expressions of HGF and VEGF mRNA in the cells that were conditioned with pioglitazone were demonstrated by RT-PCR ( Figure 5 ). Reverse transcription-polymerase chain reaction showed that HGF mRNA expression in 3T3-L1 cells conditioned with pioglitazone was enhanced by 33% compared with that in the cells conditioned without pioglitazone. On the other hand, VEGF mRNA expression in the cells was not enhanced when the cells were conditioned with pioglitazone.
Effects of pioglitazone on plasma hepatocyte growth factor and vascular endothelial growth factor levels in patients with type 2 diabetes mellitus As shown in Figure 6 , the changes of BMI and HbA 1C in the pioglitazone group were significantly higher than those in the control group. The change of plasma HGF levels in the pioglitazone group was also significantly higher than those in the control group (P ¼ 0.0479), whereas no significant differences in the change of plasma VEGF levels were observed between the pioglitazone group and the control group. In the pioglitazone group, the change of plasma HGF levels showed a positive correlation with the change of BMI (r ¼ 0.435, P ¼ 0.0329) (Figure 7) . However, the change of plasma HGF levels did not show correlation with asparate aminotransferase, alanine aminotransferase, g-glutamyl transpeptidase, fasting blood glucose, HbA 1C and plasma lipid levels in the group (data not shown).
Discussion
In this study, the supernatant of 3T3-L1 cells, which were induced of differentiation by dexamethasone, 3-isobutyl-1- 24 reported that 1-butyryl-glycerol was secreted by adipocytes, and that synthetic 1-butyryl-glycerol stimulated angiogenesis in vivo and in vitro. Leptin has also been reported to enhance tube formation in vitro. 25 A limitation of this study is that the findings are limited to demonstrating only about the HGF and the VEGF. In future studies, we should confirm whether those angiogenetic factor expressions in 3T3-L1 cells are shown and whether the supernatant of the cells treated with siRNAs for those factors suppress the tube formation of HUVECs. Also, the abnormalities of the VEGF receptor signaling pathway of the HUVECs might present under the conditions of this study. At least, the supernatant of 3T3-L1 cells did not suppress expressions of VEGF receptor 1 and 2 protein in HUVECs by Western blot analysis using phospho-specific antibodies to the VEGF receptor 1 and 2 compared with DMEM supplemented with 10% FCS (data not shown). Pioglitazone is one of the thiazolidinediones that activate the peroxisome proliferator-activated receptor g (PPARg), which is expressed primarily in adipose tissue. Forced expression of PPARg in the fibroblasts makes them differentiate into adipocytes. 26 The supernatant of the cells, differentiation in which was enhanced by addition of pioglitazone, potently promoted the tube formation of HUVECs. The enhancement of HGF mRNA expression in 3T3-L1 cells conditioned with pioglitazone was demonstrated by RT-PCR. Furthermore, plasma HGF levels increased in patients with type 2 diabetes mellitus after treatment with pioglitazone, and the change of plasma HGF levels showed a positive correlation with the change of BMI in the pioglitazone group. These results supported that the differentiation of adipocytes might enhance the HGF expression in vitro and in vivo. However, currently, the mechanism by which pioglitazone activates the HGF expression in adipocytes is not fully understood. Hepatocyte growth factor was purified from rat platelets and characterized as a growth factor for mature parenchymal hepatocytes. 27 Several recent studies have reported that HGF exhibits angiogenetic actions. Morishita et al. 28 reported that treatment with human recombinant HGF improved hindlimb ischemia in rabbits. Human recombinant HGF has been applied in therapeutic angiogenesis, as a cytokine supplement for patients with arteriosclerosis obliterans. 29 Hepatocyte growth factor is also seen as a significant cardioprotective factor because of its potent angiogenetic properties 14, 30 and because HGF can reduce restenosis after balloon injury by enhancing re-endothelialization. 31 On the other hand, plasma HGF levels are elevated in malignancies, 32 patients with atherosclerosis and proliferative diabetic retinopathy. 33, 34 The findings indicate that obesity might affect processes such as tumor angiogenesis or proliferative diabetic retinopathy mediated by HGF. Future studies should investigate whether specific inhibitors or modulators of HGF production and signaling pathways might indeed serve as targets for vascular therapies. In summary, the supernatant of differentiated 3T3-L1 cells strongly promotes tube formation of HUVECs cultured in type 1 collagen gel, and HGF secreted from 3T3-L1 cells may be the major factor regulating the tube formation. The supernatant supplemented with pioglitazone further enhances the tube formation. Pioglitazone enhanced HGF mRNA expression in 3T3-L1 cells and increased plasma HGF levels in patients with type 2 diabetes mellitus. These results suggest that agents that enhance the differentiation of adipocytes may promote tube formation of HUVECs mediated by HGF secreted by adipocytes.
